Samso: Who is Racura Oncology (ASX: RAC)? DYOR on Anti-Cancer Innovation and Heart Protection

Samso’s Noel Ong has compiled the key highlights of Racura Oncology in this note, and outlined the upcoming inflection points for the company.

In his analysis, Mr Ong writes: “Most of us have known someone who is in the predicament of being a patient of some form of cancer, so the path to finding a solution to help these patients will no doubt prove to be highly rewarding for shareholders. It goes without saying that the rewards for RAC shareholders will far exceed the current valuation.”

Read the full article here.